Related Experiment Video
Updated: Jun 19, 2026

09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Brain volume analyses and somatosensory evoked potentials in multiple system atrophy
Satoko Miyatake1, Hitoshi Mochizuki, Tetsuji Naka
1Department of Neurology, Higashi-Saitama National Hospital, Hasuda, Saitama, Japan.
Journal of Neurology
|October 1, 2009
Summary
Brain atrophy in the brainstem and cerebellum worsens with disease progression in multiple system atrophy (MSA). This progression also leads to prolonged central sensory conduction time, indicating sensory pathway involvement.
Area of Science:
- Neurology
- Neuroimaging
- Neurophysiology
Background:
- Multiple System Atrophy (MSA) is a neurodegenerative disorder.
- Understanding the progression of brain atrophy and somatosensory dysfunction is crucial for MSA management.
Purpose of the Study:
- To investigate the progression of brain atrophy and somatosensory system dysfunction in multiple system atrophy (MSA).
- To correlate brain volumes and somatosensory evoked potentials (SEPs) with clinical features and disease duration.
Main Methods:
- Utilized three-dimensional computed tomography (3D-CT) to measure relative brain volumes (cerebrum, brainstem, cerebellum) in 21 MSA patients.
- Recorded median nerve somatosensory evoked potentials (SEPs) and measured component latencies and amplitudes.
- Analyzed correlations between brain volumes, SEP parameters, and clinical features.
Main Results:
- Brainstem and cerebellar atrophy significantly worsened with disease progression.
- Central sensory conduction time (CSCT) progressively increased with disease duration, independent of patient age.
- Volume reductions in the cerebellum and brainstem serve as structural markers for disease progression.
Conclusions:
- Progressive involvement of the sensory pathway is evident in MSA.
- Brainstem and cerebellar volume reductions are reliable indicators of disease progression in MSA patients.
- Findings highlight the utility of neuroimaging and neurophysiological measures in tracking MSA progression.

